Catalog No.
DHC82405
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
MAPTL, Paired helical filament-tau, MTBT1, Microtubule-associated protein tau, TAU, Neurofibrillary tangle protein, MAPT, PHF-tau
Concentration
2.27 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P10636
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
UCB-0107, UCB0107, CAS: 2244960-75-4
Clone ID
Bepranemab
The science does not yet support regulatory approval of amyloid-targeting therapies for Alzheimer's disease based solely on biomarker evidence., PMID:40243238
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics., PMID:40011173
2024 AA criteria for Alzheimer's disease diagnosis: Mainly anchored at Aβ not tau., PMID:39470319
Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease., PMID:39073291
What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries., PMID:38618742
Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review., PMID:38405341
Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease., PMID:38267172
Passive tau-based immunotherapy for tauopathies., PMID:37620094
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies., PMID:37405389
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease., PMID:37389302
For research use only. Not for human or drug use.
